683 Capital Management’s Moderna MRNA Stock Holding History

683 Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-28,629	Closed	-$2.63M	–	150
2024 Q2	$3.4M	Buy	+28,629	New	+$3.62M	0.26%	72

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

683 Capital Management's MRNA Position: Q3 2024 in Review

683 Capital Management sold out of Moderna (MRNA) in Q3 2024, closing a stake of 28,629 shares — an estimated $2.63M sold.

683 Capital Management first reported a position in MRNA in Q2 2024 and held it in 1 quarter. The position peaked at $3.4M in Q2 2024. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

683 Capital Management reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
683 Capital Management sold 28,629 Moderna shares in Q3 2024, an estimated $2.63M.
683 Capital Management first reported a position in Moderna in Q2 2024 and held it in 1 quarter.
683 Capital Management's Moderna position peaked at $3.4M in Q2 2024.
788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on 683 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.